Valuation Formycon AG

Equities

Market Closed - Xetra Other stock markets 16:35:42 19/01/2026 GMT			After hours 19:59:35
23.15 ^EUR	-3.74%		23.25	+0.43%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	530	651.7	1,309	904.6	937.6	424.8	424.8	-
Change	-	22.97%	100.81%	-30.88%	3.65%	-54.69%	0%	-
Enterprise Value (EV) ¹	487.8	626.6	1,648	907.1	906.3	504.7	504.9	481.8
Change	-	28.46%	162.95%	-44.94%	-0.08%	-44.31%	0.04%	-4.58%
P/E ratio	-98.4x	-48.4x	33.4x	11.9x	-7.4x	-13.3x	-54.3x	12.2x
PBR	8.57x	11.6x	3.67x	1.8x	2.03x	1.03x	1.13x	1.14x
PEG	-	-0x	-0x	0.1x	0x	0.2x	0.7x	-0x
Capitalization / Revenue	15.5x	17.6x	30.8x	11.6x	13.5x	7.7x	5.01x	3.18x
EV / Revenue	14.3x	17x	38.8x	11.7x	13x	9.15x	5.96x	3.61x
EV / EBITDA	-101x	-50.6x	-104x	598x	-66x	-26.9x	-260x	8.34x
EV / EBIT	-85.2x	-47x	-92.9x	-2,458x	-38.5x	-14.1x	-34.5x	12.1x
EV / FCF	-86.1x	-42.1x	-36.1x	-29.2x	-17x	-8.34x	-19.6x	18.9x
FCF Yield	-1.16%	-2.38%	-2.77%	-3.42%	-5.87%	-12%	-5.1%	5.28%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-0.5387	-1.218	2.59	4.72	-7.18	-1.814	-0.4431	1.965
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	34.23	36.96	42.5	77.7	69.67	55.19	84.77	133.5
EBITDA ¹	-4.81	-12.39	-15.87	1.518	-13.74	-18.74	-1.94	57.74
EBIT ¹	-5.725	-13.33	-17.73	-0.369	-23.54	-35.91	-14.65	39.89
Net income ¹	-5.926	-13.48	35.99	75.8	-125.7	-32.04	-8.038	34.51
Net Debt ¹	-42.25	-25.18	338.8	2.501	-31.24	79.91	80.09	56.95
Reference price ²	53.00	59.00	86.50	56.40	53.10	24.05	24.05	24.05
Nbr of stocks (in thousands)	10,000	11,047	15,130	16,039	17,657	17,664	17,664	-
Announcement Date	17/05/21	18/05/22	27/04/23	25/04/24	27/03/25	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
FORMYCON AG	-13.26x	9.15x	-26.93x	-.--%	493M
LONZA GROUP AG	38.88x	5.65x	18.93x	0.88%	48.93B
IQVIA HOLDINGS INC.	33.47x	3.33x	14.23x	-.--%	40.48B
BEONE MEDICINES AG	103.47x	6.63x	66.61x	-.--%	37.42B
CELLTRION, INC.	55.18x	11.32x	31.46x	0.35%	31.03B
REVOLUTION MEDICINES, INC.	-21.53x	6248.57x	-20.41x	-.--%	23.25B
MEDPACE HOLDINGS, INC.	41.27x	6.69x	30.41x	-.--%	17.21B
Average	33.93x	898.76x	16.33x	0.17%	28.4B
Weighted average by Cap.	45.49x	736.48x	25.18x	0.27%